Cara Therapeutics Inc
NASDAQ:CARA

Watchlist Manager
Cara Therapeutics Inc Logo
Cara Therapeutics Inc
NASDAQ:CARA
Watchlist
Price: 18.2486 USD 243.02% Market Closed
Market Cap: $83.4m

Net Margin

-993%
Current
Declining
by 354.7%
vs 3-y average of -638.3%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-993%
=
Net Income
$-70.9m
/
Revenue
$7.1m

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-993%
=
Net Income
$-70.9m
/
Revenue
$7.1m

Peer Comparison

Country Company Market Cap Net
Margin
US
Cara Therapeutics Inc
NASDAQ:CARA
83.4m USD
Loading...
US
Eli Lilly and Co
NYSE:LLY
978.7B USD
Loading...
US
Johnson & Johnson
NYSE:JNJ
547.3B USD
Loading...
CH
Roche Holding AG
SIX:ROG
277.3B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
210B GBP
Loading...
CH
Novartis AG
SIX:NOVN
220.8B CHF
Loading...
US
Merck & Co Inc
NYSE:MRK
273B USD
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.6T DKK
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
US
Pfizer Inc
NYSE:PFE
150.2B USD
Loading...
FR
Sanofi SA
PAR:SAN
95.7B EUR
Loading...

Market Distribution

Lower than 93% of companies in the United States of America
Percentile
7th
Based on 15 072 companies
7th percentile
-993%
Low
-4 418 600% — -9.6%
Typical Range
-9.6% — 11.3%
High
11.3% — 1 135 400%
Distribution Statistics
the United States of America
Min -4 418 600%
30th Percentile -9.6%
Median 3.1%
70th Percentile 11.3%
Max 1 135 400%

Cara Therapeutics Inc
Glance View

Market Cap
83.4m USD
Industry
Pharmaceuticals

CARA Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs). The company is headquartered in Stamford, Connecticut and currently employs 84 full-time employees. The company went IPO on 2014-01-31. The firm is developing a class of product candidates KORSUVA (CR845/difelikefalin), which is a KOR agonist that targets the body’s peripheral nervous system, as well as certain immune cells. The firm is also conducting preclinical studies and clinical trials of CR845/difelikefalin-based product candidates. The firm also initiated a pharmacokinetic safety trial of multiple doses of Oral CR845 in hemodialysis patients to define bioequivalent tablet strengths to inform its ability to develop an oral tablet formulation for moderate-to-severe uremic pruritus. CR701 is a peripherally restricted, mixed-CB1/CB2 receptor agonist that selectively interacts with these cannabinoid receptor subtypes, with no off-target activities.

CARA Intrinsic Value
HIDDEN
Show
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-993%
=
Net Income
$-70.9m
/
Revenue
$7.1m
What is Cara Therapeutics Inc's current Net Margin?

The current Net Margin for Cara Therapeutics Inc is -993%, which is below its 3-year median of -638.3%.

How has Net Margin changed over time?

Over the last 3 years, Cara Therapeutics Inc’s Net Margin has decreased from -384.3% to -993%. During this period, it reached a low of -1 099.8% on Sep 30, 2024 and a high of -135.6% on Jun 30, 2022.

Back to Top